Caspian Journal of Internal Medicine
Babol University of Medical Sciences
سه شنبه 28 اسفند 1403
[Archive]
دوره 1، شماره 1 - ( 10-1388 )
جلد 1 شماره 1 صفحات 11-9 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Aghamohammadzadeh N, Tabrizi A, Niafar M, Najafipor F. Efficacy of adding glutazone to the maximum dose of glibenclamide and metformin resistant on type 2 diabetic patients. Caspian J Intern Med 2010; 1 (1) :9-11
URL: http://caspjim.com/article-1-62-fa.html
URL: http://caspjim.com/article-1-62-fa.html
Efficacy of adding glutazone to the maximum dose of glibenclamide and metformin resistant on type 2 diabetic patients. . 1388; 1 (1) :9-11
چکیده: (10803 مشاهده)
Background: To evaluate the efficacy of adding the glutazone to maximum dose of sulfonylurea and metformin in patients with poorly controlled type 2 diabetes.
Methods: Ninety six patients with type 2 diabetes who had failed medical therapy with maximal-dosage of metformin and glibenclamide received glutazone. Fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C, cholesterol and HDL levels were assessed at baseline three months later.
Results: Ninety-six patients with type 2 diabetes (74 women and 22 men) with the mean age of 55.7±9.9 years were studied. Significant reduction was seen in fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C and triglyceride levels three months after adding glutazone to therapeutic regimen (p<0.0005). There was not a significant rise in cholesterol and HDL levels before and after the new therapy.
Conclusion: The results show that the combination of glutazone, metformin and glibenclamide may result in better control of glycemic status in diabetic patients resistant to oral first-line agents.
Methods: Ninety six patients with type 2 diabetes who had failed medical therapy with maximal-dosage of metformin and glibenclamide received glutazone. Fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C, cholesterol and HDL levels were assessed at baseline three months later.
Results: Ninety-six patients with type 2 diabetes (74 women and 22 men) with the mean age of 55.7±9.9 years were studied. Significant reduction was seen in fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C and triglyceride levels three months after adding glutazone to therapeutic regimen (p<0.0005). There was not a significant rise in cholesterol and HDL levels before and after the new therapy.
Conclusion: The results show that the combination of glutazone, metformin and glibenclamide may result in better control of glycemic status in diabetic patients resistant to oral first-line agents.
نوع مطالعه: Original Article |
موضوع مقاله:
Infectious Diseases
دریافت: 1392/10/24 | پذیرش: 1392/10/24 | انتشار: 1392/10/24
دریافت: 1392/10/24 | پذیرش: 1392/10/24 | انتشار: 1392/10/24
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
